Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02230696 · ClinicalTrials.gov registry record · Phase 3
Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis
A Phase 3 study, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 951
- Enrollment target
NCT02230696 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 951 participants.
The verdict
NCT02230696, a Phase 3 study, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 951 participants
- Enrollment target
Study Summary
To compare safety and efficacy of Perrigo's steroid drug product compared with an FDA approved steroid drug product in the treatment of subjects with seasonal allergic rhinitis.
Interventions
- DRUG Placebo nasal spray
- DRUG Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 951 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02230696
The ClinicalTrials.gov registry entry for NCT02230696 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 951 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT02230696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02230696 about?
NCT02230696 is a clinical study titled "Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis". To compare safety and efficacy of Perrigo's steroid drug product compared with an FDA approved steroid drug product in the treatment of subjects with seasonal allergic rhinitis.
What is the current status of trial NCT02230696?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 951 participants. The study started on 2014-08. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02230696?
The interventions under investigation include: Placebo nasal spray (DRUG), Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray (DRUG).
Who is sponsoring clinical trial NCT02230696?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.